Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas Meeting Abstract
| Authors: | O'Connor, O. A.; Wright, J.; Moskowitz, C.; Straus, D.; Macgregor-Cortelli, B.; Muzzy, J.; Choi, P.; Schenkein, D.; Zelenetz, A. D. |
| Abstract Title: | Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas |
| Meeting Title: | 12th European Cancer Conference (ECCO 12) |
| Keywords: | tumor growth regulation; ubiquitin proteasome pathway |
| Journal Title: | EJC Supplements |
| Volume: | 1 |
| Issue: | 5 |
| Meeting Dates: | 2003 Sep 21-25 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 1359-6349 |
| Publisher: | Pergamon-Elsevier Science Ltd |
| Date Published: | 2003-09-01 |
| Start Page: | S302 |
| Language: | English |
| ACCESSION: | BCI:BCI200400108344 |
| DOI: | 10.1016/s1359-6349(03)91036-6 |
| PROVIDER: | biosis |
| Notes: | Meeting Abstract: 1009 -- 12th ECCO (European Cancer Conference) -- Copenhagen, Denmark -- September 21-25, 2003 -- Federation of European Cancer Societies -- Source: Biosis |
Altmetric
Citation Impact
BMJ Impact Analytics
